non-endocrine tumors and malignancies.

The inventor is continuing work on the development and functional characterization of the PDE11A and its variants in relation to iMAD and other tumors and malignancies of the endocrine system.

Competitive Advantage of Our Technology

Cushing Syndrome occurs in 5 to 10 per 15 million every year and 27,000 new cases of endocrine tumors are diagnosed every year. Our technology identifies a functional role of PDE11A in a new form of Cushing Syndrome and its possible role in endocrine tumors and/or other cancers. PDE inhibitors have been successfully used in the treatment of erectile dysfunction. Currently, there are three products in the market, which inhibit the different forms of PDEs for the treatment of erectile dysfunction: Sildeafil (Viagra®), Vardenafil (Levitra®) and Tadalafil (Cialis®) manufactured by Pfizer, GlaxoSmithkline/Bayer/Schering-Plough and Lily Icos respectively.

Among the marketed PDE inhibitors, Cialis® targets PDE11A and PDE5A. Most interestingly, Cialis® has no known effects on the adrenal gland and endocrine system and no PDE gene has ever been reported to be associated with endocrine or other human tumor development. Our invention of the variants of PDE11A genes and subsequent new protein PDE11A4 from one of the genetic variants have opened up the possibility of the development of new drugs for iMAD, adrenal hyperplasia and other endocrine tumors and malignancies targeting these proteins.

The three marketed PDE inhibitors mentioned above have exceeded individual worldwide sales figures of 1 billion dollars each in 2007 and have been projected to grow steadily in the next few years. Additionally, the endocrine drug market has been projected to grow to more than 40 billion dollars in the next 5 years. New PDE inhibitors and the ones in the market are all in clinical trials for several diseases such as erectile dysfunction, neurological diseases and cardiovascular diseases.

Our technology suggests that drugs that modulate PDE function can be used in treating iMAD, a rare genetic form of Cushing Syndrome with fatal implications in children. The new PDE11A gene variants that have been identified have diagnostic and therapeutic implications. PCR-based diagnostic tools can be developed to diagnose iMAD and novel antagonists targeting these PDE11A variants can be identified and developed as drugs.

Patent Estate

This technology consists of U.S. Provisional Applications Serial No. 60/761,446 entitled ''PDE11A mutations in Adrenal Diseases'' filed January 24, 2007. A PCT application has also been filed.

Next Step: Teleconference

There will be a teleconference where the principal investigator will explain this technology. Licensing and collaborative research opportunities will also be discussed. If you are interested in participating in this teleconference please call or e-mail Mojdeh Bahar; (301) 435–2950; *baharm@mail.nih.gov.* OTT will then e-mail you the date, time and number for the teleconference.

Dated: February 13, 2007.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E7–2884 Filed 2–20–07; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Amended Notice of Meeting

Notice is hereby given of a change and additional information for the meeting of the Advisory Committee to the Director, NIH, February 21, 2007, 2:30 to 4 p.m., National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892 (Telephone Conference Call) which was published in the **Federal Register** on February 8, 2007, 72 FR 5982.

The meeting will be held from 2:30 p.m. to 4:30 p.m. Also, individuals interested in attending the meeting must contact Dr. Penny W. Burgoon for telephone number and pass code. The meeting is open to the public.

Dated: February 9, 2007.

Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07–763 Filed 2–20–07; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel, Research Demonstration and Dissemination Projects (R18).

Date: March 6, 2007.

Time: 1 p.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Patricia A. Haggerty, PhD, Scientific Review Administrator, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7194, Bethesda, MD 20892–7924, 301–435–0288, *haggertp@nhibi.nih.gob.*

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: February 9, 2007.

Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07–761 Filed 2–20–07; 8:45 am]

BILLING CODE 4140–07–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Human Genome Research Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as